Letters to the Editor

Dimitri P. Mikhailidis


References


Address for Correspondence: Dr. Aydın Akyüz, Namık Kemal Üniversitesi Tip Fakültesi, Kardiyoloji Anabilim Dalı, Şehit Gökmen Yavuz Caddesi 2/1 Kat 4 D:11 Tekirdağ-Türkiye
Phone: +90 282 261 10 58
E-mail: aakyuz@nku.edu.tr

Perivascular adipose tissue in cardiovascular diseases

To the Editor,

We congratulate Grigoras et al. (1) on their comprehensive and perceptive review titled "Perivascular adipose tissue in cardiovascular diseases-an update". However, some additional comments may be of interest.

Grigoras et al. (1) report that the perivascular adipose tissue (PVAT) differs in properties depending on its anatomical location. Other authors have also reported similar findings (2). These properties, together with the anatomical structural variations, may eventually facilitate the use of a specific treatment for a specific blood vessel, in addition to the usual general measures. In this context, we also need to consider that blood vessels, at different locations, may have different receptor distributions (3).

An abnormal PVAT is probably associated with abnormal peri-organ and intra-organ fat at other sites, and this may indirectly increase the risk of vascular events (4-6). Grigoras et al. (1) also mention the potential role of various drugs on PVAT. This will be an area of considerable interest for further research (1, 6).

Grigoras et al. (1) discuss a carotid model in the context of PVAT. Indeed, other authors have reported links between the PVAT and internal carotid arteries (ICA) stenosis (7). Furthermore, the pericarotid fat density has been associated with an increased risk of stroke and transient ischemic attack in patients with unilateral ICA stenosis ≥50%-99% (8).

The review by Grigoras et al. (1) made a considerable contribution to the field discussed above.

Declaration of Interest: N.K. has given presentations, attended conferences, and participated in trials sponsored by Amgen, Astra Zeneca, Bausch Health, Boehringer Ingelheim, Elpen, MSD, Mylan, Novo Nordisk, Sanofi, and Servier. D.P.M. has given presentations and attended conferences sponsored by Amgen, AstraZeneca, and Libytec.

D Niki Katsiki, ᵃ Dimitri P. Mikhailidis¹

¹First Department of Internal Medicine, Division of Endocrinology and Metabolism, Diabetes Center, Medical School, AHEPA University Hospital; Thessaloniki-Greece

²Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL); London—United Kingdom

References


Address for Correspondence: Niki Katsiki, MD, First Department of Internal Medicine, Division of Endocrinology and Metabolism, Diabetes Center, Medical School, AHEPA University Hospital; 12 Dionysiou Street, A no Poli, PO 546 34, Thessaloniki-Greece
Phone: 0030 2310 212 352
E-mail: nikkatsiki@hotmail.com

©Copyright 2020 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.com

DOI:10.14744/AnatolJCardiol.2019.32480